MODIFICATION
B -- Assay Development Karyotyping Services
- Notice Date
- 9/8/2019
- Notice Type
- Modification/Amendment
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- HHS-NIH-NIDA-OA-19-010498-CSS
- Point of Contact
- Debra C. Hawkins, Phone: 301-827-7751
- E-Mail Address
-
debra.hawkins@nih.gov
(debra.hawkins@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA-OA-19-010498-CSS and the solicitation is issued as a Request for Quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures and FAR Part 12-Acquisition of Commercial Items. This acquisition is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1 (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). The National Institute on Drug Abuse (NIDA), Office of Acquisition on behalf of the National Institute on Aging (NIA) intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) for Assay Development Karyotyping Services with KromaTiD, Inc., 1880 Industrial Circle, Suite A, Longmont, CO, 80501-6548. The rationale for the sole-single source justification is that KaryoTid is the only source available that and assure the continuity of our on- going research experiments. (iii) This solicitation incorporates the provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2019-05, effective August 13, 2019. (iv) The associated North American Industry Classification System (NAICS) code: 541714 Research and Development in Biotechnology (except Nanobiotechnology), Size Standard: 1,000 employees. (v) Assay Development Karyotyping Services (vi) The National Institute on Aging (NIA) require assay development karyotyping services to provide genetically engineered iPSCs for the purpose of creating a national cell repository as an open resource for the scientific community and as a tool to characterize how mutations change fundamental biological properties of disease- relevant cell types. Neurodegenerative diseases are common, debilitating, and often untreatable. It is known that mutations in ~50 genes cause the majority of inherited forms of Alzheimer's disease and related dementias (ADRD). In addition, some ADRD genes function together to regulate key cellular processes, strongly suggesting the presence of converging disease mechanisms in ADRD. Genetically-defined patient cohorts now exist and are growing, setting the stage for future precision medicine trials. However, in order to develop effective targeted therapies for these defined cohorts, we need a deeper mechanistic understanding of how individual gene mutations cause disease. In addition, we need to systematically identify and characterize converging ADRD disease pathways, which may be ideal drug targets because single drugs could be effective in patients with mutations in different, but functionally related, genes. To aid in this effort, we require the creation of isogneic panels of genome-engineered human iPSC lines harboring mutations associated with neurodegenerative diseases. Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the specific requirements below. Specific Requirements: (1) Cell culture and prep for dGH assay for 16 cell lines; (2) Assay, imaging, and scoring for human dosimetry for 16 samples, with 3 processed images per sample; and (3) transfer of original image files. The platform used must provide: (1) Repeated karyotype analysis of cells in culture at various time, e.g. following low-density cell expansion that would mimic changes post genome editing/clonal outgrowth; (2) Chromosomal preparation technique that includes analog nucleotide incorporation during the DNA replication phase of the cell cycle to enable exonuclease daughter strand degradation that leaves dGH prepped chromosomes single- stranded; (3) For metaphase chromosomes, assay must be capable of providing sequence, location and orientation information in a single assay; (4) Enable inversion detection with a resolution that is orders of magnitude greater than any competing technique; (5) Query entire chromosomes or individual chromatids (single- stranded applications) in interphase or metaphase cells; and (6) In a single assay, must detect the broadest possible spectrum of chromosome rearrangements, including those assayable by standard FISH technologies (e.g. translocations between chromosomes) as well as intra-chromosomal rearrangements such as cryptic inversions Key Personnel: The contractor shall designate a project manager as a contact point for Government's Contracting Officer's Representative. Government Responsibilities: The government will provide iPSC starting material to contractor. Delivery or Deliverables: The contractor shall delivery assay results for: (1) Cell culture and prep for dGH assay for 16 cell lines; and (2) Assay, imaging, and scoring for human dosimetry for 16 samples. Reporting Requirements: The contractor is required to provide documentation regarding assay results for: (1) General method of Cell culture and prep for dGH assay for 16 cell lines; and (2) Assay, imaging, and scoring for human dosimetry for 16 samples Assay, imaging, and scoring for human dosimetry for 16 samples electronically via reporting transfer through email to the Government's Contracting Officer's Representative. Data Rights: The contractor shall comply with Section 508 of the Rehabilitation Act (29 U.S.C. § 794d), as amended by the Workforce Investment Act of 1998 (P.L. 105-220), August 7, 1998. (vii) Government's Anticipated Period of Performance / Delivery Date: The Government anticipates a 2-month period of performance After Receipt of Order (ARO). Delivery Point: FOB Destination. Delivery Location: National Institute on Aging, Baltimore, Maryland 21224. The successful offeror shall coordinate delivery arrangements with the customer prior to shipment. The Loading Dock hours are as follows: 8:00 am to 4:30 pm Eastern Time, Monday through Friday except on Federal holidays. All products delivered must contain a Packing Slip (with serial numbers as applicable). (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The factors used to evaluate offers are the unique technical and performance capabilities of product and cost. Technical and past performance, when combined, are significantly more important than cost or price. Technical Criteria: Factor 1: Technical Approach. The Contractor's proposal shall address each area of the statement of work requirements in sufficient detail to demonstrate a clear understanding of the efforts to be performed and the skill level required to perform them. Factor 2: Past Performance: The Contractor shall provide details of at least one prior project on similar in nature to the project specification outlined herein. Past Performance shall be evaluated for relevance to the current requirement. (x) Offerors are advised to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items, with its offer. (xi) FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items, applies to this acquisition. (xiii) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiv) Defense Priorities and Allocations System (DPAS) and assigned rating, is not applicable to this solicitation. (xv) All quotations or offers are due 12:00 Noon, Eastern Time, on September 13, 2019, and must reference the solicitation number noted herein. Quotations or offers must be submitted electronically to the contact person identified herein at debra.hawkins@nih.gov. Fax responses will not be accepted. (xvi) For information regarding this solicitation contact: Debra C. Hawkins Contractor, Acquisition Policy Analyst II, at 301-827-7751.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-OA-19-010498-CSS/listing.html)
- Place of Performance
- Address: National Institute on Aging, Baltimore, Maryland, 21224, United States
- Zip Code: 21224
- Zip Code: 21224
- Record
- SN05435575-W 20190910/190908230036-4c5b2c50afaaa77b0bce810d7a002e0e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |